• Angela Katz, Andrzej Niemierko, Irene Gage, Sheila Evans, Margaret Shaffer, Thomas Fleury, Frederick P Smith, Peter E Petrucci, Richard Flax, Cynthia Drogula, and Colette Magnant.
• Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. abkatz@partners.org
• J Surg Oncol. 2006 Jun 1; 93 (7): 550-8.

BackgroundWho should undergo a completion dissection following identification of a +sentinel lymph node (SLN) is controversial.MethodsThe records of 1,133 patients who underwent SLN mapping were reviewed. The association between patient, tumor, and treatment characteristics and the presence of +SLNs and +nonSLNs was analyzed using two-way tables of frequency counts and Pearson chi2 test. Possible predictors of +SLNs and +nonSLNs were analyzed using simple and multiple logistic regression.ResultsOne thousand one hundred forty-eight SLN procedures were performed. 367 procedures (32%) yielded +SLNs. For patients with a +SLN, on multiple logistic regression analysis LVSI, increasing numbers of +SLNs, decreasing numbers of negative SLNs, and increasing size of the largest SLN metastasis were statistically significantly associated with increased likelihood of nonSLN involvement. No subgroup was identified that did not have a significant rate of nonSLN involvement on completion axillary dissection, except those who had a large number of negative SLNs (> or =3) and small size of the largest SLN metastasis (<10 mm).ConclusionsA definitive answer to the question of who needs a completion axillary dissection awaits the results of ongoing trials. In the interim, our data does not support eliminating dissection for any subgroup of patients with +SLNs.Copyright 2006 Wiley-Liss, Inc.

27 keywords...

hide…